Vitamin D receptor activation is a feasible therapeutic target to impair adrenocortical tumorigenesis

Objective: To evaluate the therapeutic potential of vitamin D receptor (VDR) signaling in adrenocortical carcinoma (ACC) cells. Methods: We evaluated VDR's methylation pattern in H295R ACC cells, and investigated the effects of calcitriol and seocalcitol treatments on adrenocortical tumorigenesis. Results: VDR was hypermethylated and underexpressed in basal H295R cells. Treatments with calcitriol and seocalcitol restored VDR signaling, resulted in antiproliferative effects, and impaired Wnt/B-catenin signaling. RNAseq of treated cells demonstrated VDR activation on steroid hormones biosynthesis and Rap1 signaling, among others. In vivo, seocalcitol constrained the growth of H295R xenografts and reduced autonomous tumor steroid secretion without hypercalcemia-associated side effects. Conclusions: H295R cells present VDR hypermethylation, which can be responsible for its underexpression and signaling inactivation under basal conditions. VDR signaling promoted antiproliferative effects in vitro and in vivo, suggesting that it may be a potential therapeutic target for ACC and a valuable tool for patient's clinical management.

Automated summary

The therapeutic potential of vitamin D receptor (VDR) signaling in adrenocortical carcinoma (ACC) cells was evaluated. The study found that VDR was hypermethylated and underexpressed in ACC cells. Treatment with calcitriol and seocalcitol restored VDR signaling, resulting in antiproliferative effects and impaired Wnt/B-catenin signaling. In vivo experiments showed that seocalcitol constrained the growth of ACC xenografts and reduced tumor steroid secretion without side effects. These findings suggest that VDR signaling may be a potential therapeutic target for ACC.